Hitting the Right Spot: Advances in the Treatment of NSCLC with Uncommon EGFR Mutations

Abstract

An understanding of the biology of uncommon epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) is evolving. These mutations are important for the selection of targeted therapy and the development of resistance. The advent of genomic profiling has led to guideline-recommended molecular testing to identify patients with NSCLC who carry uncommon EGFR mutations to aid in the selection of appropriate targeted therapy. This article discusses the efficacy and safety of current and emerging targeted therapies for the treatment of uncommon EGFR mutations in NSCLC to aid in developing patient-specific treatment plans.